Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers
Authors
Krebs, Matthew GLopez, J
El-Khoueiry, A
Bang, Y
Postel-Vinay, S
Abida, W
Carter, Louise
Xu, W
Im, S
Pierce, A
Frewer, P
Berges, A
Cheung, A
Stephens, C
Felicetti, B
Dean, E
Hollingsworth, S
Affiliation
The Christie NHS Foundation Trust and The University of Manchester ManchesterIssue Date
2018
Metadata
Show full item recordCitation
Krebs MG, Lopez J, El-Khoueiry A, Bang Y-J, Postel-Vinay S, Abida W, et al. Phase I study of AZD6738, an inhibitor of ataxia telangiectasia Rad3-related (ATR), in combination with olaparib or durvalumab in patients (pts) with advanced solid cancers. Cancer Res. 2018;78(13).Journal
Cancer ResearchDOI
10.1158/1538-7445.AM2018-CT026Additional Links
https://dx.doi.org/10.1158/1538-7445.AM2018-CT026Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.AM2018-CT026